These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16569878)

  • 21. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of point mutations in the gyrA gene of Helicobacter pylori isolates in Slovenia.
    Kese D; Gubina M; Kogoj R; Strasek K; Tepes B
    Hepatogastroenterology; 2009; 56(91-92):925-9. PubMed ID: 19621731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy.
    Matsuzaki J; Suzuki H; Tsugawa H; Nishizawa T; Hibi T
    J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S7-10. PubMed ID: 20586870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.
    Lee JW; Kim N; Nam RH; Kim JM; Park JY; Lee SM; Kim JS; Lee DH; Jung HC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7629-36. PubMed ID: 26416863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
    Sharara AI; Chaar HF; Racoubian E; Moukhachen O; Barada KA; Mourad FH; Araj GF
    Helicobacter; 2004 Jun; 9(3):255-61. PubMed ID: 15165262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substitutions of amino acids in alpha-helix-4 of gyrase A confer fluoroquinolone resistance on Clostridium perfringens.
    Rafii F; Park M
    Arch Microbiol; 2007 Feb; 187(2):137-44. PubMed ID: 17051403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.
    Luzarraga V; Cremniter J; Plouzeau C; Michaud A; Broutin L; Burucoa C; Pichon M
    J Antimicrob Chemother; 2024 Oct; 79(10):2633-2639. PubMed ID: 39126340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid detection of fluoroquinolone resistance by isothermal chimeric primer-initiated amplification of nucleic acids from clinical isolates of Neisseria gonorrhoeae.
    Horii T; Monji A; Uemura K; Nagura O
    J Microbiol Methods; 2006 Jun; 65(3):557-61. PubMed ID: 16278026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children.
    Liu G; Xu X; He L; Ding Z; Gu Y; Zhang J; Zhou L
    Helicobacter; 2011 Oct; 16(5):356-62. PubMed ID: 21923681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
    Coskun-Ari FF; Bosgelmez-Tinaz G
    Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany.
    Wueppenhorst N; Stueger HP; Kist M; Glocker E
    J Antimicrob Chemother; 2009 Apr; 63(4):648-53. PubMed ID: 19190100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G).
    Preisler A; Heisig P
    J Antimicrob Chemother; 2009 Feb; 63(2):290-4. PubMed ID: 19033246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights into resistance of Helicobacter pylori against third- and fourth-generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations.
    Salehi N; Attaran B; Eskini N; Esmaeili M; Sharifirad A; Sadeghi M; Mohammadi M
    Helicobacter; 2019 Oct; 24(5):e12628. PubMed ID: 31282059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
    Suzuki Y; Nakajima C; Tamaru A; Kim H; Matsuba T; Saito H
    Int J Antimicrob Agents; 2012 May; 39(5):435-9. PubMed ID: 22421328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.
    Fukuda H; Kishii R; Takei M; Hosaka M
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1649-53. PubMed ID: 11353607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
    Guo Y; Pei X; Liu X
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France.
    Garcia M; Raymond J; Garnier M; Cremniter J; Burucoa C
    Antimicrob Agents Chemother; 2012 Jan; 56(1):550-1. PubMed ID: 22064536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.